Prostate Cancer Clinical Trial

C11-Sodium Acetate PET/CT Imaging for Metastatic Disease in Intermediate-to-high Risk Prostate Adenocarcinoma

Summary

Positron emission tomography using carbon-11 acetate (AC-PET) may help find local or distant metastases from prostate cancer. This clinical trial is studying how this imaging test may help influence the choice and extent of initial treatments, and subsequent treatments.

View Full Description

Full Description

OBJECTIVES:

Determine the role of positron emission tomography using carbon-11 acetate (AC-PET) in the initial and subsequent management of patients with prostate cancer at intermediate or high risk for recurrence after initial curative therapy.
Compare the value of AC-PET in predicting recurrence of prostate cancer with that of conventional approaches (e.g., pre-operative clinical staging, prostate-specific antigen, Gleason score, prostate and lymph node histology) in these patients.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Male patients will be studied who have prostate cancer:

Diagnosed with prostate adenocarcinoma
Has completed conventional staging examinations, including histologic evaluation with Gleason score, CT scan of the abdomen and pelvis, and whole-body bone scintigraphy Candidate for curative prostatectomy OR curative radiotherapy OR staging lymphadenectomy prior to surgery

Deemed to be at intermediate or high risk for recurrence or metastatic disease after initial curative treatment, as defined by of one of the following:

Gleason score >= 7 or PSA >= 10
Gleason score < 7 or PSA <10 ng/mL with positive surgical margins, biopsy proven or suspected regional nodal involvement or conventional imaging showing limited metastatic disease that may be amenable to directed radiotherapy
Rising or non-responding PSA

Exclusion Criteria:

< 18 years old
claustrophobic patients

Study is for people with:

Prostate Cancer

Phase:

Phase 2

Estimated Enrollment:

300

Study ID:

NCT01530269

Recruitment Status:

Completed

Sponsor:

Phoenix Molecular Imaging

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Phoenix Molecular Imaging
Phoenix Arizona, 85040, United States

How clear is this clinincal trial information?

Study is for people with:

Prostate Cancer

Phase:

Phase 2

Estimated Enrollment:

300

Study ID:

NCT01530269

Recruitment Status:

Completed

Sponsor:


Phoenix Molecular Imaging

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider